Kijimicin
Kijimicin is a polyether ionophore antibiotic originally discovered in Actinomadura sp. MI215-NF3. inhibits HIV-1 replication and reduces the infectivity of progeny viral particles. Kijimicin exhibits inhibitory activity against intracellular T. gondii (IC50 = 45.6 nM), extracellular parasites (IC50 = 216.6 pM) and C. parvum (IC50 = 7.7 nM), and controls acute T. gondii infection in mice. Kijimicin can be used for research on HIV, toxoplasmosis, cryptosporidiosis, and bacterial infections.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 129297-22-9
- Fòrmula: C37H64O11
- Peso molecular:684.90
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Antibiotic
MoreVer todos los productos específicos de isoformas Parasite
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
HIV-1 2.2 μg/mL (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HFF | IC50 |
46.5 μM
|
Exhibits low cytotoxicity against HFF cells.
Exhibits low cytotoxicity against HFF cells.
|
books/R100000039-I11123919 |
| HCT-8 | CC50 |
> 20 μM
|
Shows no significant cytotoxicity in HCT-8.
Shows no significant cytotoxicity in HCT-8.
|
42075832 |
In Vitro
Kijimicin (7 days) inhibits HIV-1 replication in acutely infected H9 cells with an IC50 of 2.2 μg/mL, and shows little cytotoxicity (IC50 = 88 μg/mL)[1].
Kijimicin (0.1-1000 μg/mL; 72 h) inhibits HIV-1 replication in chronically infected U937 cells[1].
Kijimicin (0.01, 0.1, 1.0 μg/mL; 7 days) reduces the infectivity of progeny HIV-1 viral particles from H9 cells by more than 1 log[1].
Kijimicin exhibits antimicrobial activity against Gram-positive bacteria including Staphylococcus aureus FDA 209P (MIC < 0.78 μg/mL), Bacillus cereus ATCC 10702 (MIC < 0.78 μg/mL), and Micrococcus luteus PCI 1001 (MIC < 0.78 μg/mL)[2].
Kijimicin (7.7 nM; 48 h) inhibits C. parvum growth in HCT-8 cells with an IC50 of 7.7 nM and a CC50 > 20 μM (selectivity index = 2585)[3].
Kijimicin (1-300 nM; 72 h) inhibits intracellular T. gondii RH-GFP growth in HFF cells with an IC50 of 45.6 nM and a selectivity index of 1019.7[4].
Kijimicin (1-2000 pM; 1 h) inhibits extracellular T. gondii RH-GFP invasion into Vero cells with an IC50 of 216.6 pM and a selectivity index of 214,681.4[4].
Kijimicin (50 nM; 24 h) induces morphological changes in T. gondii tachyzoites, including cell swelling and multiple intracellular vacuole-like structures[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HFF cells
-
Concentration:100 nM to 300 μM
-
Incubation Time:72 h
-
Result:Showed an IC50 of 46.5 μM.
-
Cell Line:HFF cells infected with T. gondii RH-GFP
-
Concentration:1, 3, 10, 30, 100, 300 nM
-
Incubation Time:72 h
-
Result:Inhibited intracellular T. gondii growth with IC50 of 45.6 nM and SI of 1019.7.
-
Cell Line:Vero cells
-
Concentration:1, 3, 10, 30, 100, 300, 1000, 2000 pM
-
Incubation Time:1 h pretreatment + 24 h post-infection
-
Result:Inhibited T. gondii invasion into Vero cells with IC50 of 216.6 pM and SI of 214,681.4.
-
Cell Line:Vero cells infected with T. gondii RH-GFP
-
Concentration:50 nM
-
Incubation Time:24 h
-
Result:Induced morphological changes in tachyzoites including cell swelling and vacuole-like structures.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:T. gondii PLK-GFP-infected female BALB/c mice (6-8 weeks old)[4]
-
Dosage:3, 10 mg/kg
-
Administration:i.p.; once daily for 7 days
-
Result:Improved survival rate (91.7%) and reduced clinical signs from 7 to 17 days post-infection(10 mg/kg).
Improved survival rate (66.7%) and reduced clinical signs.
Chemical Information
-
No. CAS 129297-22-9
-
Peso molecular 684.90
-
Fòrmula C37H64O11
-
SMILES
C[C@H](C([C@H](C)[C@@H](OC)[C@H]1C)O[C@]21CC[C@@H]([C@H]3CC[C@@](O3)([C@@H]4O[C@@H]([C@@]5(O)O[C@](C[C@@H]5C)(C)[C@H](O)CC)C[C@@H]4C)C)O2)[C@@H](OC)[C@H](C)C(O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Yamauchi T, et al. Mechanistic effects of kijimicin on inhibition of human immunodeficiency virus replication. Mol Cell Biochem. 1993 Feb 17;119(1-2):35-41. [Content Brief]
[2]. Takahashi Y, et al. Kijimicin, a polyether antibiotic. J Antibiot (Tokyo). 1990 Apr;43(4):441-3. [Content Brief]
[3]. Kubota R, et al. Development of a Luciferase-Based In Vitro Assay to Evaluate the Efficacy of Anti-Cryptosporidial Drugs Against Cryptosporidium parvum. Pharmaceuticals (Basel). 2026 Apr 3;19(4):576. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Kijimicin Related Classifications
HY-123444 Related Classifications
Powered by Bioz
Keywords
- Kijimicin
- 129297-22-9
- Antibiotic
- HIV
- Reverse Transcriptase
- Parasite
- Bacterial
- Human immunodeficiency virus
- polyether ionophore
- antibiotic
- HIV-1
- antiviral
- anti-HIV
- reverse transcriptase
- Toxoplasma gondii
- anti-Toxoplasma
- Cryptosporidium parvum
- anti-Cryptosporidium
- Apicomplexa
- antiparasitic
- anticoccidial
- Eimeria tenella
- Actinomadura
- Inhibitor
- inhibitor
- inhibit